TBHQ

TBHQ (tert-Butylhydroquinone) is a widely used Nrf2 activator, protects against Doxorubicin (DOX) -induced cardiotoxicity through activation of Nrf2[1]. TBHQ (tert-Butylhydroquinone) is also an ERK activator; rescues Dehydrocorydaline (DHC) -induced cell proliferation inhibitionin melanoma[2].

Product Specifications

CAS Number

[1948-33-0]

Product Name Alternative

Tert-Butylhydroquinone

UNSPSC

12352005

Hazard Statement

H302+H312, H315, H317, H319, H410

Target

Apoptosis; Autophagy; ERK; Ferroptosis; Keap1-Nrf2

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; MAPK/ERK Pathway; NF-κB; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/TBHQ.html

Purity

99.93

Solubility

DMSO : ≥ 56.66 mg/mL

Smiles

OC1=CC=C(O)C=C1C(C)(C)C

Molecular Formula

C10H14O2

Molecular Weight

166.22

Precautions

H302+H312, H315, H317, H319, H410

References & Citations

[1]Lin-Feng Wang, et al. Tert-butylhydroquinone ameliorates doxorubicin-induced cardiotoxicity by activating Nrf2 and inducing the expression of its target genes. Am J Transl Res. 2015; 7 (10) : 1724–1735.|[2]Hu H, et al. Dehydrocorydaline inhibits cell proliferation, migration and invasion via suppressing MEK1/2-ERK1/2 cascade in melanoma.Onco Targets Ther. 2019 Jul 2;12:5163-5175.|[3]XIAOJING SHI, et al. Tert-butylhydroquinone attenuates the ethanol-induced apoptosis of and activates the Nrf2 antioxidant defense pathway in H9c2 cardiomyocytes.Int J Mol Med. 2016 Jul; 38 (1) : 123–130.|[4]Sukumari-Ramesh S, et al. Post-Injury Administration of Tert-butylhydroquinone Attenuates Acute Neurological Injury AfterIntracerebral Hemorrhage in Mice.J Mol Neurosci. 2016 Apr;58 (4) :525-31.